Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00232089
Status:
COMPLETED
Last Update Posted:
2016-11-18
First Post:
2005-09-08
Brief Title:
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being done to evaluate the safety tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain Tegaserod will be evaluated at 6mg twice daily and placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None